These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36429043)

  • 1. Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo.
    Shimizu T; Sugihara E; Takeshima H; Nobusue H; Yamaguchi R; Yamaguchi-Iwai S; Fukuchi Y; Ushijima T; Muto A; Saya H
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
    Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
    Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
    Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
    J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.
    Liu M; Wang D; Li N
    Biochem Biophys Res Commun; 2016 Apr; 473(1):168-173. PubMed ID: 27012205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells.
    Tsuda Y; Tanikawa C; Miyamoto T; Hirata M; Yodsurang V; Zhang YZ; Imoto S; Yamaguchi R; Miyano S; Takayanagi H; Kawano H; Nakagawa H; Tanaka S; Matsuda K
    Sci Rep; 2017 Sep; 7(1):10739. PubMed ID: 28878391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.
    Chachad D; Patel LR; Recio CV; Pourebrahim R; Whitley EM; Wang W; Su X; Xu A; Lee DF; Lozano G
    Cancer Res; 2023 Jul; 83(14):2297-2311. PubMed ID: 37205631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.
    Zhang Y; Hu Q; Li G; Li L; Liang S; Zhang Y; Liu J; Fan Z; Li L; Zhou B; Ruan Y; Yang X; Chen S; Mu T; Wang G; Xiong S
    Cell Physiol Biochem; 2018; 48(3):1099-1111. PubMed ID: 30041188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
    Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
    Mizuarai S; Yamanaka K; Kotani H
    Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma.
    Liu DD; Kang Y
    Genes Dev; 2017 Sep; 31(18):1823-1824. PubMed ID: 29051386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
    Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
    Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
    [No Abstract]   [Full Text] [Related]  

  • 12. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
    Xiong S; Tu H; Kollareddy M; Pant V; Li Q; Zhang Y; Jackson JG; Suh YA; Elizondo-Fraire AC; Yang P; Chau G; Tashakori M; Wasylishen AR; Ju Z; Solomon H; Rotter V; Liu B; El-Naggar AK; Donehower LA; Martinez LA; Lozano G
    Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11145-50. PubMed ID: 25024203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.
    van der Deen M; Taipaleenmäki H; Zhang Y; Teplyuk NM; Gupta A; Cinghu S; Shogren K; Maran A; Yaszemski MJ; Ling L; Cool SM; Leong DT; Dierkes C; Zustin J; Salto-Tellez M; Ito Y; Bae SC; Zielenska M; Squire JA; Lian JB; Stein JL; Zambetti GP; Jones SN; Galindo M; Hesse E; Stein GS; van Wijnen AJ
    J Biol Chem; 2013 Jul; 288(29):21307-21319. PubMed ID: 23720736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
    Long X; Lin XJ
    J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.
    Schwartzenberg-Bar-Yoseph F; Armoni M; Karnieli E
    Cancer Res; 2004 Apr; 64(7):2627-33. PubMed ID: 15059920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
    Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
    J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
    Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
    J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.
    Walia MK; Ho PM; Taylor S; Ng AJ; Gupte A; Chalk AM; Zannettino AC; Martin TJ; Walkley CR
    Elife; 2016 Apr; 5():. PubMed ID: 27070462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state.
    Mori T; Sato Y; Miyamoto K; Kobayashi T; Shimizu T; Kanagawa H; Katsuyama E; Fujie A; Hao W; Tando T; Iwasaki R; Kawana H; Morioka H; Matsumoto M; Saya H; Toyama Y; Miyamoto T
    Oncogene; 2014 Aug; 33(33):4236-41. PubMed ID: 24336323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.
    Wang JY; Chen CM; Chen CF; Wu PK; Chen WM
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.